Topical cannabidiol may safely improve the healing of digital ulcers and boost quality of life, while also easing pain in people with systemic sclerosis (SSc), a study in Italy suggests. Benefits were also seen in increasing the amount of sleep per night for those given the treatment. The study,…
Emerald Health Pharmaceuticals’ cannabis-derived therapy, EHP-101, eased the symptoms of systemic sclerosis by preventing blood vessel damage, and reducing fibrosis and inflammation in a study using mice. The study, “Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for Systemic Sclerosis,” was published in…
Emerald Health’s lead cannabinoid-derived investigational therapy, EHP-101, shows promise as a possible oral treatment for scleroderma, a mouse study shows. A second cannabinoid-derivative, called VCE-004.3, also showed potential to enhance anti-inflammatory and anti-fibrotic responses in animal models of scleroderma. Both EHP-101 and VCE-004.3 are derived from cannabidiol…
Using cannabis or marijuana for medicinal purposes is a hot topic right now among patients and health practitioners. It’s regularly touted as a pain reliever for many chronic illnesses. According to the National Cancer Institute, here are some of the facts about medical marijuana and its suggested uses: It’s…
A research team has developed a cannabinoid-based drug that stimulates not only one, but two, receptors believed to be involved in fibrosis development in scleroderma. The drug, VCE-004.8, prevented the formation of fibrosis-promoting myofibroblasts in culture and stopped fibrotic changes in a mouse model of dermal fibrosis. Findings from these…
Get regular updates to your inbox.